A Phase 3 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia and Enlarged Prostate, sponsored by Eli Lilly and Company. Completed at 65 sites in 13 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2013-02-27.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 3rd largest by enrollment, is one of 3 that started in 2010, is one of 10 in phase 3, and was the 11th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Assiut University
Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 6
First in 2004; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 696 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 258 across the 26 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 26 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
17 studies in Prostatic Hyperplasia by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 17 finished, 16 (94%) have results posted.
Among the 17 studies in Prostatic Hyperplasia by Eli Lilly and Company, this one is the 3rd largest by enrollment, is one of 4 that started in 2010, is one of 9 in phase 3, and was the 12th registered.
Eli Lilly and Company’s Prostatic Hyperplasia studies by the year they started, since 2004.
1 of the studies testing tadalafil in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654413Beni-Suef UniversityTamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 17 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the efficacy and safety of once daily tadalafil when taken with finasteride as a treatment for men with signs and symptoms of Benign Prostatic Hyperplasia and demonstrable prostate enlargement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have not taken the following treatments within the indicated duration and agree not to use at any time during the study:
Exclusion Criteria:
Drug: Tadalafil · Drug: Finasteride
Drug: Placebo · Drug: Finasteride
5 milligrams (mg) administered orally, once daily for 26 weeks
Also known as: Cialis, LY#450190
Administered orally, once daily for 26 weeks
5mg administered orally, once daily for 26 weeks
Change in Total International Prostate Symptom Score (IPSS) From Baseline to 12 Weeks
The International Prostate Symptom Score (IPSS) is a rating scale for severity of lower urinary tract symptoms (LUTS). The IPSS has a 7-component questionnaire. Each question is scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.
Time frame: Baseline, 12 weeks
Change in Total International Prostate Symptom Score (IPSS) From Baseline to 4 and 26 Weeks
The International Prostate Symptom Score (IPSS) is a rating scale for severity of lower urinary tract symptoms (LUTS). The IPSS has a 7-component questionnaire. Each question is scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.
Time frame: Baseline, 4 weeks, 26 weeks
Change in International Prostate Symptom Score (IPSS) Subscores Index From Baseline to 4, 12, and 26 Weeks
IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the 7-component IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms), with total subscore of the 3 questions for irritative subscore range from 0 to 15. IPSS voiding (obstructive) subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms), with total subscore of the 4 questions of the obstructive score range from 0 to 20. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.
Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks
Change in International Prostate Symptom Score (IPSS) Quality of Life Index From Baseline to 4, 12, and 26 Weeks
IPSS Quality of Life Index assesses participant response to the following question: "If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?" Response options are Delighted (0); Pleased (1); Mostly satisfied (2); Mixed-about equally satisfied and dissatisfied (3); Mostly dissatisfied (4); Unhappy (5); Terrible (6), with a total range of 0-6. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.
Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks
Change in International Index of Erectile Function (IIEF) - Erectile Function Domain Scores From Baseline to 4, 12, and 26 Weeks
Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.
Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks
Change in International Index of Erectile Function (IIEF) - Overall Satisfaction Domain Scores From Baseline to 4, 12, and 26 Weeks
Self-reported overall satisfaction over the past 4 weeks. IIEF-Overall Satisfaction is the sum of Questions 13 and 14 of IIEF questionnaire. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher total scores indicate higher satisfaction. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.
Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks
Change in International Index of Erectile Function (IIEF) - Intercourse Satisfaction Domain Scores From Baseline to 4, 12, and 26 Weeks
Self-reported intercourse satisfaction over the past 4 weeks. IIEF-intercourse satisfaction is the sum of Questions 6, 7 and 8 of the IIEF. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions of 0 to 15. Higher total scores indicate higher satisfaction. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.
Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks
Change in International Index of Erectile Function (IIEF) - Orgasmic Function Domain Scores From Baseline to 4, 12, and 26 Weeks
Orgasmic Function domain scores is the sum of Questions 9 and 10 from the IIEF questionnaire. Scores range from 0 (low/no orgasm) to 5 (high orgasm) for each question, with the total possible score for the 2 questions ranging from 0 to 10. Higher total scores indicate higher orgasm. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.
Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks
Change in International Index of Erectile Function (IIEF) - Sexual Desire Domain Scores From Baseline to 4, 12, and 26 Weeks
Sexual desire domain scores is the sum of Questions 11 and 12 from the IIEF questionnaire. Scores range from 1 (low/no desire) to 5 (high desire) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher total scores indicate higher desire. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.
Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks
Patient Global Impression of Improvement (PGI-I) at 26 Weeks
Patient Global Impression of Improvement (PGI-I) measures the participant's perception of improvement at the time of assessment compared with the start of treatment. Number of participants is reported by the categorized score ranging from 1 (very much better) to 7 (very much worse).
Time frame: 26 weeks
Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 26 Weeks
The TSS-BPH was a validated participant-rated instrument that measured participant satisfaction with treatment based on a 13-item questionnaire. It consists of 10 items on a Likert-like scale with scores ranging from 1 (higher satisfaction) to 5 (lower satisfaction), 1 item with score ranging from 0 (higher satisfaction) to 5 (lower satisfaction), and 2 yes/no questions. The mean score for each participant ranges from 0.9 (higher satisfaction) to 5.0 (lower satisfaction). Data presented are the average of mean scores for each treatment group.
Time frame: 26 weeks
Clinician Global Impression of Improvement (CGI-I) at 26 Weeks
Clinician Global Impression of Improvement (CGI-I) measures clinician's perception of participant improvement at the time of assessment compared with the start of treatment. Number of participants is reported by the categorized score ranging from 1 (very much better) to 7 (very much worse).
Time frame: 26 weeks
Change in Post Void Residual (PVR) Volume From Baseline to 26 Weeks
Postvoid Residual Volume (PVR) is determined using a portable, calibrated ultrasound device. It consists of the average of a minimum of 3 scans where the residual bladder volume was calculated by averaging the most accurate of the 3 imaging attempts.
Time frame: Baseline, 26 weeks
Change in International Index of Erectile Function (IIEF) Question 3 and 4 Scores From Baseline to 4, 12, and 26 Weeks
IIEF Question 3 asks how often a participant was able to penetrate his partner over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). IIEF Question 4 asks whether/how often a participant was able to maintain an erection after penetration over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.
Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks
| Milestone | Screening-Washout and Placebo Lead-In | Tadalafil | Placebo |
|---|---|---|---|
| Started | 1070 | 0 | 0 |
| Completed | 696 | 0 | 0 |
| Not completed | 374 | 0 | 0 |
| Withdrew: Entry criteria not met | 258 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 83 | 0 | 0 |
| Withdrew: Physician decision | 12 | 0 | 0 |
| Withdrew: Sponsor decision | 10 | 0 | 0 |
| Withdrew: Lost to follow-up | 10 | 0 | 0 |
| Milestone | Screening-Washout and Placebo Lead-In | Tadalafil | Placebo |
|---|---|---|---|
| Started | 0 | 346 | 350 |
| Received at least 1 dose of study drug | 0 | 345 | 350 |
| Completed | 0 | 306 | 286 |
| Not completed | 0 | 40 | 64 |
| Withdrew: Adverse event | 0 | 4 | 10 |
| Withdrew: Death | 0 | 1 | 1 |
| Withdrew: Entry criteria not met | 0 | 14 | 17 |
| Withdrew: Protocol violation | 0 | 2 | 8 |
| Withdrew: Withdrawal by subject | 0 | 6 | 13 |
| Withdrew: Physician decision | 0 | 2 | 0 |
| Withdrew: Sponsor decision | 0 | 5 | 6 |
| Withdrew: Lack of efficacy | 0 | 3 | 5 |
| Withdrew: Lost to follow-up | 0 | 3 | 4 |
The International Prostate Symptom Score (IPSS) is a rating scale for severity of lower urinary tract symptoms (LUTS). The IPSS has a 7-component questionnaire. Each question is scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| Change in Total International Prostate Symptom Score (IPSS) From Baseline to 12 Weeks | -5.18 ± 0.32 | -3.76 ± 0.32 |
The International Prostate Symptom Score (IPSS) is a rating scale for severity of lower urinary tract symptoms (LUTS). The IPSS has a 7-component questionnaire. Each question is scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| 4 weeks | -3.95 ± 0.29 | -2.29 ± 0.28 |
| 26 weeks | -5.51 ± 0.33 | -4.47 ± 0.33 |
IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the 7-component IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms), with total subscore of the 3 questions for irritative subscore range from 0 to 15. IPSS voiding (obstructive) subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms), with total subscore of the 4 questions of the obstructive score range from 0 to 20. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| IPSS storage (irritative) subscore - 4 weeks | -1.27 ± 0.14 | -0.76 ± 0.14 |
| IPSS storage (irritative) subscore - 12 weeks | -1.74 ± 0.14 | -1.34 ± 0.14 |
| IPSS storage (irritative) subscore - 26 weeks | -2.00 ± 0.15 | -1.66 ± 0.15 |
| IPSS voiding (obstructive) subscore - 4 weeks | -2.65 ± 0.19 | -1.47 ± 0.19 |
| IPSS voiding (obstructive) subscore - 12 weeks | -3.41 ± 0.21 | -2.37 ± 0.21 |
| IPSS voiding (obstructive) subscore - 26 weeks | -3.50 ± 0.22 | -2.77 ± 0.22 |
IPSS Quality of Life Index assesses participant response to the following question: "If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?" Response options are Delighted (0); Pleased (1); Mostly satisfied (2); Mixed-about equally satisfied and dissatisfied (3); Mostly dissatisfied (4); Unhappy (5); Terrible (6), with a total range of 0-6. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| 4 weeks | -0.63 ± 0.07 | -0.32 ± 0.06 |
| 12 weeks | -0.95 ± 0.07 | -0.76 ± 0.07 |
| 26 weeks | -1.10 ± 0.08 | -0.92 ± 0.08 |
Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| 4 weeks | 3.71 ± 0.50 | -1.14 ± 0.51 |
| 12 weeks | 4.71 ± 0.56 | 0.63 ± 0.57 |
| 26 weeks | 4.71 ± 0.57 | -0.02 ± 0.60 |
Self-reported overall satisfaction over the past 4 weeks. IIEF-Overall Satisfaction is the sum of Questions 13 and 14 of IIEF questionnaire. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher total scores indicate higher satisfaction. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| 4 weeks | 0.91 ± 0.15 | -0.10 ± 0.15 |
| 12 weeks | 1.38 ± 0.16 | 0.31 ± 0.17 |
| 26 weeks | 1.61 ± 0.17 | 0.40 ± 0.18 |
Self-reported intercourse satisfaction over the past 4 weeks. IIEF-intercourse satisfaction is the sum of Questions 6, 7 and 8 of the IIEF. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions of 0 to 15. Higher total scores indicate higher satisfaction. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| 4 weeks | 1.36 ± 0.24 | -0.46 ± 0.24 |
| 12 weeks | 1.68 ± 0.26 | 0.08 ± 0.27 |
| 26 weeks | 1.72 ± 0.27 | -0.26 ± 0.28 |
Orgasmic Function domain scores is the sum of Questions 9 and 10 from the IIEF questionnaire. Scores range from 0 (low/no orgasm) to 5 (high orgasm) for each question, with the total possible score for the 2 questions ranging from 0 to 10. Higher total scores indicate higher orgasm. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| 4 weeks | 0.90 ± 0.22 | -0.63 ± 0.23 |
| 12 weeks | 1.08 ± 0.23 | 0.18 ± 0.24 |
| 26 weeks | 0.89 ± 0.24 | -0.18 ± 0.25 |
Sexual desire domain scores is the sum of Questions 11 and 12 from the IIEF questionnaire. Scores range from 1 (low/no desire) to 5 (high desire) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher total scores indicate higher desire. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| 4 weeks | 0.46 ± 0.12 | -0.47 ± 0.12 |
| 12 weeks | 0.56 ± 0.13 | -0.23 ± 0.13 |
| 26 weeks | 0.71 ± 0.13 | -0.05 ± 0.14 |
Patient Global Impression of Improvement (PGI-I) measures the participant's perception of improvement at the time of assessment compared with the start of treatment. Number of participants is reported by the categorized score ranging from 1 (very much better) to 7 (very much worse).
| participants | Tadalafil | Placebo |
|---|---|---|
| 1 = Very much better | 21 | 29 |
| 2 = Much better | 124 | 82 |
| 3 = Little better | 102 | 112 |
| 4 = No change | 49 | 52 |
| 5 = A little worse | 10 | 5 |
| 6 = Much worse | 2 | 7 |
| 7 = Very much worse | 1 | 1 |
The TSS-BPH was a validated participant-rated instrument that measured participant satisfaction with treatment based on a 13-item questionnaire. It consists of 10 items on a Likert-like scale with scores ranging from 1 (higher satisfaction) to 5 (lower satisfaction), 1 item with score ranging from 0 (higher satisfaction) to 5 (lower satisfaction), and 2 yes/no questions. The mean score for each participant ranges from 0.9 (higher satisfaction) to 5.0 (lower satisfaction). Data presented are the average of mean scores for each treatment group.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 26 Weeks | 2.0 ± 0.63 | 2.1 ± 0.66 |
Clinician Global Impression of Improvement (CGI-I) measures clinician's perception of participant improvement at the time of assessment compared with the start of treatment. Number of participants is reported by the categorized score ranging from 1 (very much better) to 7 (very much worse).
| participants | Tadalafil | Placebo |
|---|---|---|
| 1 = Very much improved | 23 | 22 |
| 2 = Much improved | 129 | 97 |
| 3 = Minimally improved | 98 | 106 |
| 4 = No change | 47 | 48 |
| 5 = Minimally worse | 5 | 10 |
| 6 = Much worse | 5 | 6 |
| 7 = Very much worse | 0 | 1 |
Postvoid Residual Volume (PVR) is determined using a portable, calibrated ultrasound device. It consists of the average of a minimum of 3 scans where the residual bladder volume was calculated by averaging the most accurate of the 3 imaging attempts.
| milliliters (mL) | Tadalafil | Placebo |
|---|---|---|
| Change in Post Void Residual (PVR) Volume From Baseline to 26 Weeks | -24.8 ± 73.08 | -23.1 ± 66.15 |
IIEF Question 3 asks how often a participant was able to penetrate his partner over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). IIEF Question 4 asks whether/how often a participant was able to maintain an erection after penetration over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| Question 3 - 4 weeks | 0.42 ± 0.09 | -0.32 ± 0.09 |
| Question 3 - 12 weeks | 0.72 ± 0.09 | 0.04 ± 0.09 |
| Question 3 - 26 weeks | 0.68 ± 0.10 | -0.07 ± 0.10 |
| Question 4 - 4 weeks | 0.49 ± 0.09 | -0.21 ± 0.09 |
| Question 4 - 12 weeks | 0.74 ± 0.09 | 0.13 ± 0.09 |
| Question 4 - 26 weeks | 0.68 ± 0.10 | 0.06 ± 0.10 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Screening-Washout and Placebo Lead-In | — | 1/1,070 (0.1%) | 153/1,070 (14.3%) |
| Tadalafil | — | 9/345 (2.6%) | 105/345 (30.4%) |
| Placebo | — | 5/350 (1.4%) | 94/350 (26.9%) |
| Event | Screening-Washout and Placebo Lead-In | Tadalafil | Placebo |
|---|---|---|---|
| CholangitisHepatobiliary disorders | 0/1070 | 1/345 | 0/350 |
| Device related infectionInfections and infestations | 0/1070 | 1/345 | 0/350 |
| GastroenteritisInfections and infestations | 0/1070 | 1/345 | 0/350 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/1070 | 1/345 | 0/350 |
| Back painMusculoskeletal and connective tissue disorders | 0/1070 | 1/345 | 0/350 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/1070 | 1/345 | 0/350 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/1070 | 1/345 | 0/350 |
| Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1070 | 1/345 | 0/350 |
| Ischaemic strokeNervous system disorders | 0/1070 | 1/345 | 0/350 |
| Urinary retentionRenal and urinary disorders | 0/1070 | 1/345 | 1/350 |
| Event | Screening-Washout and Placebo Lead-In | Tadalafil | Placebo |
|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 6/1070 | 15/345 | 6/350 |
| HeadacheNervous system disorders | 12/1070 | 12/345 | 12/350 |
| DyspepsiaGastrointestinal disorders | 7/1070 | 8/345 | 2/350 |
| InfluenzaInfections and infestations | 6/1070 | 8/345 | 8/350 |
| DiarrhoeaGastrointestinal disorders | 5/1070 | 5/345 | 6/350 |
| NasopharyngitisInfections and infestations | 13/1070 | 5/345 | 3/350 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 5/1070 | 5/345 | 5/350 |
| DysuriaRenal and urinary disorders | 1/1070 | 1/345 | 5/350 |
| Erectile dysfunctionReproductive system and breast disorders | 0/1070 | 1/345 | 5/350 |
| Gastric ph decreasedInvestigations | 0/1070 | 4/345 | 1/350 |
| Age Continuous(years) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Mean | 63.8 ± 7.50 | 63.6 ± 7.85 | 63.7 ± 7.68 |
| Sex: Female, Male(Participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 345 | 350 | 695 |
| Ethnicity (NIH/OMB)(Participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 9 |
| Not Hispanic or Latino | 39 | 41 | 80 |
| Unknown or Not Reported | 302 | 304 | 606 |
| Race (NIH/OMB)(Participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 33 | 37 | 70 |
| Asian | 5 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 15 | 21 |
| White | 298 | 296 | 594 |
| More than one race | 3 | 1 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| United States | 43 | 46 | 89 |
| Greece | 18 | 12 | 30 |
| Turkey | 26 | 19 | 45 |
| Russian Federation | 32 | 37 | 69 |
| Italy | 21 | 25 | 46 |
| France | 21 | 9 | 30 |
| Mexico | 33 | 37 | 70 |
| Canada | 30 | 28 | 58 |
| Argentina | 46 | 41 | 87 |
| Belgium | 7 | 16 | 23 |
| Poland | 32 | 39 | 71 |
| Brazil | 12 | 13 | 25 |
| Germany | 24 | 28 | 52 |
| Lower urinary tract symptoms (LUTS) severity(participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Moderate (IPSS<20) | 238 | 235 | 473 |
| Severe (IPSS≥20) | 106 | 114 | 220 |
| Unknown | 1 | 1 | 2 |
| Peak urine flow rate(participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| <10 milliliters/second (mL/sec) | 154 | 169 | 323 |
| 10-15 mL/sec | 190 | 180 | 370 |
| >15 mL/sec | 1 | 1 | 2 |
| Postvoid residual volume (PVR)(milliliters (mL)) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Mean | 65.5 ± 60.69 | 62.6 ± 59.57 | 64.1 ± 60.10 |
7 further baseline measures are reported on the registry.
The record gives a start of Sep 2010, a primary completion of Feb 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil